Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
| Market Cap | $71.60M-69.7% |
| Revenue (ttm) | $5.31M |
| Net Income | -$72.09M-24.3% |
| EPS | -$0.75+9.6% |
| Shares Out | 124.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,190,850 |
| Open | $0.70 |
| Previous Close | $0.66 |
| Day's Range | $0.56 - $0.70 |
| 52-Week Range | $0.56 - $3.06 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | $3.00(+421.65%) |
| Earnings Date | Nov 13, 2026 |
About MIST
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating MIST in the last 3 months, one vote each. Issuer-paid research is not counted.
$MIST stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MIST holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MIST's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MIST Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MIST Revenue by Segment
| License revenue | $2.00M | 67.50% |
| Product revenues | $963.00K | 32.50% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MIST patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MIST from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MIST
| SURISimplify Propel Opportunities ETF | $2.22M |
| GWXState Street SPDR S&P International Small Cap ETF | $18.58K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MIST’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| SURI | Simplify Propel Opportunities ETF | 2.88% |
Weight is the stock’s share of each fund’s holdings.